Management of pancreatic head adenocarcinoma: From where to where?

被引:6
|
作者
Dolay, Kemal [1 ]
Malya, Fatma Umit [2 ]
Akbulut, Sami [3 ,4 ]
机构
[1] Istinye Univ, Liv Hosp, Dept Surg, Div Hepatopancreatobiliary Surg, TR-34340 Istanbul, Turkey
[2] Bezmialem Vakif Univ, Dept Surg, Fac Med, TR-34093 Istanbul, Turkey
[3] Inonu Univ, Dept Surg, Fac Med, Elazig Yolu 10 Km, TR-44280 Malatya, Turkey
[4] Inonu Univ, Liver Transplant Inst, Fac Med, Elazig Yolu 10 Km, TR-44280 Malatya, Turkey
来源
关键词
Pancreatic head cancer; Standard pancreatectomy; Extended pancreatectomy; Regional lymphadenectomy; Extended lymphadenectomy; LYMPH-NODE RATIO; INDEPENDENT PROGNOSTIC-FACTOR; MESENTERIC VEIN RESECTION; EXTENDED LYMPHADENECTOMY; DUCTAL ADENOCARCINOMA; STANDARD LYMPHADENECTOMY; PERINEURAL INVASION; ARTERIAL RESECTION; CLINICAL-SIGNIFICANCE; SURGICAL-TREATMENT;
D O I
10.4240/wjgs.v11.i3.143
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Pancreatic head adenocarcinoma (PHAC) is one of the most aggressive malignancies, and it has low long-term survival rates. Surgery is the only option for long-term survival. The difficulties associated with PHAC include higher frequencies of regional or distant lymph node metastases and vascular involvement, and positive resection margins in pancreatic and retroperitoneal tissues. Radical resections increase margin negativity and life expectancy; however, the extend of the surgery applied is controversial. Thus, western and eastern centers may use different approaches. Multiorgan, peripancreatic nerve plexus, and vascular resections have been discussed in relation to radical surgery for pancreatic cancer as have the roles of neoadjuvant and adjuvant therapy regimens. Determining the appropriate limits for surgery, standardizing definitions and surgical techniques according to guidelines, and centralizing pancreatic surgery within high-volume institutions to reduce mortality and morbidity rates are among the most important issues to consider. In this review, we evaluate the basic concepts underlying and the roles of radical surgery for PHAC, and lymphadenectomy, nerve plexus, retroperitoneal tissue, vascular, and multivisceral resections, total pancreatectomy, and liver metastases are discussed.
引用
收藏
页码:143 / 154
页数:12
相关论文
共 50 条
  • [1] Locally Advanced Pancreatic Adenocarcinoma: Where Are We and Where Are We Going?
    Richter, Joshua
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2010, 11 (02): : 139 - 143
  • [2] Locally Advanced Pancreatic Adenocarcinoma: Where Are We and Where Are We Going?
    Chang, Bryan W.
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2011, 12 (02): : 101 - 105
  • [3] Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going
    Coppola, Alessandro
    Farolfi, Tommaso
    La Vaccara, Vincenzo
    Iannone, Immacolata
    Giovinazzo, Francesco
    Panettieri, Elena
    Tarallo, Mariarita
    Cammarata, Roberto
    Coppola, Roberto
    Caputo, Damiano
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (11)
  • [4] Management Accounting: Where From, Where Now, Where To?
    Van der Stede, Wim A.
    JOURNAL OF MANAGEMENT ACCOUNTING RESEARCH, 2015, 27 (01) : 171 - 176
  • [5] Second Line Therapy for Advanced Pancreatic Adenocarcinoma: Where Are We and Where Are We Going?
    Brus, Christina
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2010, 11 (04): : 321 - 323
  • [6] Pancreatic adenocarcinoma: Beyond first line, where are we?
    Cherri, Sara
    Noventa, Silvia
    Zaniboni, Alberto
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (17) : 1847 - 1863
  • [7] Pancreatic adenocarcinoma: Beyond first line, where are we?
    Sara Cherri
    Silvia Noventa
    Alberto Zaniboni
    World Journal of Gastroenterology, 2021, 27 (17) : 1847 - 1863
  • [8] Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
    Marc Hilmi
    Laurent Bartholin
    Cindy Neuzillet
    World Journal of Gastroenterology, 2018, (20) : 2137 - 2151
  • [9] Investigational Biomarkers for Pancreatic Adenocarcinoma: Where Do We Stand?
    Datta, Jashodeep
    Vollmer, Charles M., Jr.
    SOUTHERN MEDICAL JOURNAL, 2014, 107 (04) : 256 - 263
  • [10] Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
    Hilmi, Marc
    Bartholin, Laurent
    Neuzillet, Cindy
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (20) : 2137 - 2151